Parkinson’s Disease Therapeutics Market Size & Share - by Drug Class (Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, Others), By Route of Administration (Oral, Injectable, Nasal, Transdermal, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and by Region: Global & Forecast, 2024-2033

  • 2023-12-05
  • 198
  • Healthcare & Life Sciences
Market Overview

Parkinson’s Disease Therapeutics Market Size is projected to achieve a value of USD 5.21 Billion in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 12.32 Billion by 2033 with a CAGR of 8.8% during the forecast period 2024-2033.

Parkinson's disease is a neurological condition that impairs movement. Tremors, stiffness, delayed mobility, and poor balance are some of its symptoms. It is caused by the death of dopamine-producing brain cells, which interferes with the brain's ability to communicate with the muscles, making control and coordination difficult. The specific origin is still unknown, but with time, symptoms get worse. In order to enhance the quality of life for people who are impacted, treatment attempts to manage symptoms with medicine, counseling, and occasionally surgery.

             Get more in-depth information of this reports – Request Free Sample

The market for Parkinson's disease therapeutics is driven by an aging population and ongoing scientific developments. Important motivators include the development of novel therapeutics like gene therapy and stem cell transplantation, as well as technological advancements in drug delivery methods. Moreover, rising healthcare costs and awareness both support market expansion. All of these things work together to improve patient outcomes, expand the market, and increase treatment alternatives, all of which promote a more all-encompassing approach to managing Parkinson's disease.

Market Scope

Report Attributes


Market Size in 2023

USD 5.21 Billion

Market Forecast in 2033

USD 12.32 Billion

CAGR % 2024-2033


Base Year


Historic Data


Forecast Period


Report USP


Production, Consumption, company share, company heatmap, company production capacity, growth factors and more

Segments Covered

By Drug Class, By Route of Administration, By Distribution Channel and By Region

Regional Scope

North America, Europe, APAC, South America and Middle East and Africa

Country Scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria


Parkinson’s Disease Therapeutics Industry:  Dynamics & Restrains

Market Drivers

  • Growing prevalence of Parkinson's disease - The Parkinson’s Disease Therapeutics Market is significantly influenced by the disease's rising prevalence. The demand for effective therapies is increasing due to the rising frequency of this neurodegenerative condition caused by an aging worldwide population. This rising incidence not only makes improved treatment options more urgently needed, but it also fuels efforts in research and development to create cutting-edge medications and therapies. The market for disease-specific treatments is thus expected to grow as a result of pharmaceutical companies and healthcare institutions being encouraged to invest more in the search for cutting-edge solutions that aim to alleviate symptoms and improve quality of life for Parkinson's sufferers.
  • Development of new and more effective treatments - The Parkinson’s Disease Therapeutics Market is expected to rise mostly due to the development of more sophisticated and effective therapies. Novel drugs and state-of-the-art remedies like deep brain stimulation are developed as a result of research breakthroughs. These novel therapies provide better symptom control, which may impede the course of the illness and boost patient outcomes. These solutions raise patient expectations, encourage investment, and increase market competitiveness among pharmaceutical companies as they show potential in meeting unmet needs. In the end, the search for new therapies elevates the field of Parkinson's therapeutics overall by growing the market and stoking hope for improved disease management.

Market Restrains

  • Limited awareness and understanding of the disease - The market expansion of Parkinson's disease is severely limited by a lack of knowledge and comprehension of the condition. Inadequate public awareness of the early signs frequently causes a delay in diagnosis and treatment. This ignorance hinders patients' access to clinical trials and accessible treatments, which delays the uptake of treatments. Misconceptions regarding the illness can also result in stigmatization and a decline in support for research projects. Timely referrals and suitable care techniques are further hampered by healthcare workers' lack of thorough understanding. To improve disease care, increase patient participation, and create a more favorable environment for Parkinson's therapy developments, it is imperative to close these awareness gaps.

Research Report Following Segments

Market- By Drug Class Analysis

By Drug Class, the Parkinson’s Disease Therapeutics Market is Categories into Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, Others. The Levodopa segment accounts for the largest share of around 32% in 2022.

Levodopa remains an important component of Parkinson's disease treatment due to its remarkable symptom-relieving properties. It is still commonly used today because it increases dopamine levels in the brain.

The following segments are part of an in-depth analysis of the global market for Parkinson's disease therapies:

Market Segments


By Route of Administration

·         Oral

·         Injectable

·         Nasal

·         Transdermal

·         Others

By Distribution Channel

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

Market Regional Analysis

North America dominate the Parkinson’s Disease Therapeutics Market with the highest revenue generating market with share of more than 46%. North America is home to a sophisticated healthcare system with a large number of hospitals and clinics. This makes it easier for patients to receive therapy for Parkinson's disease. Among the leading pharmaceutical companies in the world with North American headquarters are AbbVie, Pfizer, and Novartis. These companies are investing large sums of money in the research and development of innovative treatments for Parkinson's disease.

Europe is the second-largest market for Parkinson’s Disease Therapeutics market. Due to Parkinson’s disease affects an estimated 1.2 million people in Europe, making it a very common condition. Europe's governments are investing a large amount of money in the search for new Parkinson's disease treatments.

Asia Pacific is expected to be the fastest-growing market for Parkinson’s Disease Therapeutics during the forecast period. The aging population in this region is the biggest and fastest-growing worldwide. As a result, there are more persons suffering from Parkinson's disease. People in the area are finding it more affordable to have Parkinson's disease therapy as their disposable income rises. In the area, there is a rising awareness of Parkinson's disease, which is encouraging more people to seek treatment.

Competitive Analysis

The Parkinson’s Disease Therapeutics Market is dominated by a few large companies, such as

·         Zydus Cadila

·         Novartis AG

·         GlaxoSmithKline Plc.

·         AbbVie Inc.

·         Merck & Co., Inc.

·         Dr. Reddy’s Laboratories

·         Teva Pharmaceutical Industries Ltd.

·         Sun Pharmaceutical Industries Ltd.

·         Cipla Inc.

·         Denali Therapeutics Inc.

·         Boehringer Ingelheim International GmbH

·         Biogen Inc.

·         Prevail Therapeutics

·         Voyager Therapeutics

·         Eli Lilly and Company


Recent Development


  • In February 2021, Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines to people affected by neurological diseases, announced that it had received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental new drug application for GOCOVRI (amantadine) extended release capsules, gaining a second indication for the product as an adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients.

  • August 2020, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved NOURIANZ (istradefylline) as an add-on treatment to levodopa or carbidopa in adult patients with Parkinson’s disease (PD) experiencing ‘OFF’ episodes. ‘Off’ episodes are incapacitating periods of partial or total immobility that patients with advanced Parkinson's disease experience.

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process

We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).


The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.

Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.

Frequently Asked Questions

What is the market size of Parkinson’s Disease Therapeutics Market in 2022?

Parkinson’s Disease Therapeutics Market was valued at USD 4.31 Billion in 2022.

What is the growth rate for the Parkinson’s Disease Therapeutics Market?

Parkinson’s Disease Therapeutics Market size will increase at approximate CAGR of 8.8% during the forecasted period.

Which are the top companies operating within the market?

Major companies operating within the Parkinson’s Disease Therapeutics Market are Zydus Cadila, Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Denali Therapeutics Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Prevail Therapeutics, Voyager Therapeutics and Eli Lilly and Company.

Which region dominates the Parkinson’s Disease Therapeutics Market?

North America dominates the market with an active share of 46%.


Select a license type that suits your business needs

Single User Access

US $3950

Only Three Thousand Nine Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $4950

Only Four Thousand Nine Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $5950

Only Five Thousand Nine Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI